The pharmacological inhibition of NF-κB activity significantly reduced the vulnerability of neurons overexpressing TDP-43 to toxicity induced by microglia and glutamate, identifying NF-κB as a potential therapeutic target for ALS. This evidence concerns the gene NFKB1 and amyotrophic lateral sclerosis.